Quick summary: New research has found that semaglutide, the active ingredient in Ozempic and Wegovy, is disproportionately associated with reports of depression and anxiety compared with similar medications, with suicidal ideation also appearing more frequently in real world data. Although mood related side effects account for roughly 1% of all reported issues and larger studies show no clear causal link, these signals highlight the need for clinicians to screen patients mental health histories thoroughly before prescribing injectable weight loss treatments. This matters for wellbeing and healthcare practice because rapid physical changes can outpace emotional adjustment, particularly among those with unrecognised mood disorders, so building mental health monitoring into treatment plans from the start alongside follow up appointments could reduce risks and improve safety for users.
New research has found that semaglutide, the active ingredient in Ozempic and Wegovy, is disproportionately associated with reports of depression and anxiety, raising questions about how mental health is monitored in patients using injectable weight loss treatments. The findings were published in Pharmaceuticals.
The analysis drew on real-world data and found that semaglutide users reported higher rates of psychological side effects compared with patients on similar medications. Suicidal ideation also appeared more frequently in reports involving semaglutide than in those for comparable drugs.
These findings contrast with larger clinical and observational studies. Both the European Medicines Agency and the US Food and Drug Administration reviewed data on GLP-1 receptor agonists and found no clear causal link to suicidal thoughts or behaviour, though the FDA acknowledged a small risk cannot be entirely ruled out.
Mood-related side effects, including anxiety, account for roughly 1% of all reported side effects linked to semaglutide. An analysis of more than 8,200 reports in the FDA’s Adverse Event Reporting System found associations between GLP-1 medications and symptoms such as nervousness, insomnia, and changes in eating behaviour, though associations do not confirm causation.
A separate study of medical records covering 4 million people found that semaglutide was actually linked to a lower likelihood of being diagnosed with anxiety, in both people with diabetes and those using it for weight loss.
By comparison, users of tirzepatide, found in Mounjaro and Zepbound, reported significantly higher rates of injection site reactions. Liraglutide, an older drug in the same class, appears to carry a comparatively lower risk profile for both mental health symptoms and dosing errors.
Clinicians are urging healthcare providers to assess patients’ mental health histories before starting treatment. Rapid physical changes brought about by these medications can outpace emotional adjustment, and individuals seeking weight-related care often have higher baseline rates of mood disorders that go unrecognised.
Dr Blen Tesfu, a physician and medical advisor at Welzo, said that straightforward steps can reduce risk. “Screening patients before using medications such as semaglutide and tirzepatide will help determine if the treatment is safe. The doctor needs to know your history regarding mental health, the level of stress you have experienced, and how you relate to food.” She added that follow-up appointments are important, and that patients should be encouraged to report any mood changes, sleep problems, or anxiety promptly.
Misuse of these medications through unregulated online sources remains a growing public health concern, with many obtaining them for cosmetic purposes without medical supervision. Researchers and clinicians broadly agree that mental health monitoring should be built into treatment plans from the outset.